S&P 500   3,360.63 (-0.58%)
DOW   29,158.12 (-0.82%)
QQQ   233.70 (-0.40%)
AAPL   315.90 (-2.79%)
FB   216.67 (+1.16%)
MSFT   186.41 (+0.57%)
GOOGL   1,515.24 (-0.23%)
AMZN   2,138.03 (+0.15%)
CGC   22.48 (+1.58%)
NVDA   289.63 (-0.06%)
BABA   218.50 (-0.51%)
MU   57.36 (-1.97%)
TSLA   846.74 (+5.84%)
AMD   56.80 (+2.69%)
T   38.10 (-0.39%)
ACB   1.61 (+1.90%)
F   8.06 (-0.49%)
NFLX   386.36 (+1.57%)
PRI   135.38 (-1.07%)
BAC   34.11 (-2.12%)
DIS   138.38 (-0.83%)
GILD   66.97 (-0.87%)
S&P 500   3,360.63 (-0.58%)
DOW   29,158.12 (-0.82%)
QQQ   233.70 (-0.40%)
AAPL   315.90 (-2.79%)
FB   216.67 (+1.16%)
MSFT   186.41 (+0.57%)
GOOGL   1,515.24 (-0.23%)
AMZN   2,138.03 (+0.15%)
CGC   22.48 (+1.58%)
NVDA   289.63 (-0.06%)
BABA   218.50 (-0.51%)
MU   57.36 (-1.97%)
TSLA   846.74 (+5.84%)
AMD   56.80 (+2.69%)
T   38.10 (-0.39%)
ACB   1.61 (+1.90%)
F   8.06 (-0.49%)
NFLX   386.36 (+1.57%)
PRI   135.38 (-1.07%)
BAC   34.11 (-2.12%)
DIS   138.38 (-0.83%)
GILD   66.97 (-0.87%)
S&P 500   3,360.63 (-0.58%)
DOW   29,158.12 (-0.82%)
QQQ   233.70 (-0.40%)
AAPL   315.90 (-2.79%)
FB   216.67 (+1.16%)
MSFT   186.41 (+0.57%)
GOOGL   1,515.24 (-0.23%)
AMZN   2,138.03 (+0.15%)
CGC   22.48 (+1.58%)
NVDA   289.63 (-0.06%)
BABA   218.50 (-0.51%)
MU   57.36 (-1.97%)
TSLA   846.74 (+5.84%)
AMD   56.80 (+2.69%)
T   38.10 (-0.39%)
ACB   1.61 (+1.90%)
F   8.06 (-0.49%)
NFLX   386.36 (+1.57%)
PRI   135.38 (-1.07%)
BAC   34.11 (-2.12%)
DIS   138.38 (-0.83%)
GILD   66.97 (-0.87%)
S&P 500   3,360.63 (-0.58%)
DOW   29,158.12 (-0.82%)
QQQ   233.70 (-0.40%)
AAPL   315.90 (-2.79%)
FB   216.67 (+1.16%)
MSFT   186.41 (+0.57%)
GOOGL   1,515.24 (-0.23%)
AMZN   2,138.03 (+0.15%)
CGC   22.48 (+1.58%)
NVDA   289.63 (-0.06%)
BABA   218.50 (-0.51%)
MU   57.36 (-1.97%)
TSLA   846.74 (+5.84%)
AMD   56.80 (+2.69%)
T   38.10 (-0.39%)
ACB   1.61 (+1.90%)
F   8.06 (-0.49%)
NFLX   386.36 (+1.57%)
PRI   135.38 (-1.07%)
BAC   34.11 (-2.12%)
DIS   138.38 (-0.83%)
GILD   66.97 (-0.87%)
Log in

NASDAQ:MAPP - MAP Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MAP Pharmaceuticals, Inc, incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:MAPP
CUSIPN/A
WebN/A
Phone+1-302-6587581

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive MAPP News and Ratings via Email

Sign-up to receive the latest news and ratings for MAPP and its competitors with MarketBeat's FREE daily newsletter.


MAP Pharmaceuticals (NASDAQ:MAPP) Frequently Asked Questions

What is MAP Pharmaceuticals' stock symbol?

MAP Pharmaceuticals trades on the NASDAQ under the ticker symbol "MAPP."

Has MAP Pharmaceuticals been receiving favorable news coverage?

News stories about MAPP stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MAP Pharmaceuticals earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned news headlines about the healthcare company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the next few days. View News Stories for MAP Pharmaceuticals.

How can I contact MAP Pharmaceuticals?

MAP Pharmaceuticals' mailing address is 2525 Dupont Dr, IRVINE, CA 92612-1531, United States. The healthcare company can be reached via phone at +1-302-6587581.


MarketBeat Community Rating for MAP Pharmaceuticals (NASDAQ MAPP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  162
MarketBeat's community ratings are surveys of what our community members think about MAP Pharmaceuticals and other stocks. Vote "Outperform" if you believe MAPP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAPP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel